.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, using up the top scientific research location at Sanofi.Quigley will certainly start Sept. 30 as the French Big Pharma's primary clinical officer as well as international chief of research, Sanofi told Tough Biotech in an emailed claim.Quigley is substituting Frank Nestle, M.D., that left behind Sanofi this spring surrounded by an international overhaul of the company's R&D device. Nestle, who devoted eight years with the pharma, dove over to Deerfield Control, where he currently functions as a partner on the therapies staff and also chief executive officer of the firm's restorative exploration and progression procedures.
Quigley will definitely participate in Sanofi coming from a San Francisco-based biotech that's in stealth, depending on to his LinkedIn profile page. He is actually presently provided as the provider's co-founder, president as well as chief executive officer.Since August 2021, Quigley has functioned as a venture partner at SV Health and wellness Investors, a healthcare fund supervisor along with current expenditures in biotechs including BioAge, Cerevance, Dualitas Rehabs as well as Nimbus Rehabs, among others. Quigley in the past stored the best spot at Dualitas, a biotech that stays in stealth, according to STAT.The soon-to-be Sanofi leader likewise earlier helmed Therini Bio, an immunotherapy biotech operating to build treatments for neurodegenerative diseases steered by general problems.Just before investing the last handful of years in biotech, Quigley has an also longer performance history in Major Pharma, most just recently acting as Gilead's senior vice president of investigation biology till the summer of 2021. Before that, he clocked in greater than 4 years around numerous leadership jobs at Bristol Myers Squibb and also functioned as a clinical director at Johnson & Johnson's Janssen upper arm just before that.Sanofi claimed Quigley's objective in his new task would be actually to "optimize our likelihood of excellence through optimum partnerships throughout our company as well as beyond, taking best-in-class technology and also cultivating and also sourcing new industry-leading talent along with a dedication to variety," according to an internal memo secured by STAT.